CJC-1295: The Long-Acting GHRH That Rewrote GH Therapy

What CJC-1295 Actually Is

CJC-1295 is a 29-amino-acid peptide derived from the first 29 residues of native growth hormone–releasing hormone (GHRH). The native molecule is degraded within minutes by dipeptidyl peptidase-IV (DPP-IV) — your body chops it almost as fast as the hypothalamus releases it. ConjuChem engineered CJC-1295 by substituting four amino acids to resist DPP-IV cleavage, creating the version called Modified GRF (1-29), also known as CJC-1295 without DAC.

The second version, CJC-1295 with DAC (Drug Affinity Complex), adds a maleimidopropionic acid linker that covalently binds to circulating serum albumin. That extends half-life from minutes to roughly 6–8 days. The tradeoff is also the problem — DAC produces what researchers call a “GH bleed,” a sustained elevation that flattens the natural pulsatile pattern your pituitary evolved to release.

The Biochemistry Most Articles Skip

The GHRH receptor is a class B G-protein-coupled receptor that, when activated, raises intracellular cAMP via Gαs coupling. Rising cAMP activates protein kinase A, which phosphorylates CREB and drives transcription of the GH gene. Within minutes, pre-formed GH is released from secretory vesicles. Studies in healthy adults show CJC-1295 (modified GRF 1-29) at 100 mcg produces a peak GH response of approximately 8–12 ng/mL within 30 minutes, versus a baseline of 0.5–2 ng/mL.

The half-life numbers matter for protocol design. Modified GRF 1-29 has a serum half-life of roughly 30 minutes — long enough to drive a full GH pulse, short enough to clear before the next physiological pulse window. CJC-1295 with DAC has a serum half-life of 6–8 days, with detectable activity for 14+ days. This is why DAC-free is the version tony huge prefers and why the “DAC vs no DAC” question is the first one any honest protocol guide answers.

Downstream of pituitary GH release: GH binds the GH receptor on hepatocytes, activating JAK2-STAT5 signaling and transcribing IGF-1. Serum IGF-1 rises over 24–72 hours. IGF-1 is what produces most of the muscle and recovery effects people attribute to GH itself.

Tony Huge Laws of Biochemistry Physics — Law 5 Applied

CJC-1295 is a textbook illustration of the Tony Huge Laws of Biochemistry Physics, specifically Law 5: Independent Receptor Stacking. GH release in the pituitary is gated by two independent signaling pathways — GHRH (cAMP-mediated, drives synthesis and release) and ghrelin (Gq-mediated through GHSR, drives release and suppresses somatostatin). These are physically distinct receptors on the same somatotroph cell, converging on the same outcome.

This is why CJC-1295 + ipamorelin produces a GH pulse three to five times larger than either compound alone. You’re activating two non-competing receptor systems and removing the somatostatin governor at the same time. Stacking two GHRHs together gives diminishing returns (competition for the same receptor). Stacking GHRH + GHRP gives additive — closer to multiplicative — release. Law 5 in action.

Natural Plus Protocol

Dosing: Modified GRF 1-29 (no DAC), 100 mcg subcutaneous, 1–3 times per day. The classic tony huge stack is 100 mcg CJC-1295 + 100 mcg ipamorelin per shot. Inject in a fasted state (insulin blunts GH pulses) and wait 20–30 minutes before eating.

Cycle: 8–12 weeks on, 4 weeks off. Long-term continuous use blunts pituitary responsiveness — the same receptor desensitization that makes once-promising compounds turn into placebos by month four.

Timing: Pre-bed dose is non-negotiable — it stacks with your natural slow-wave-sleep GH pulse. Pre-workout dose is optional; the GH spike contributes to lipolysis during training. Skip the post-workout shot; it competes with insulin and food.

Bloodwork: IGF-1 at baseline, week 4, and week 12. Target range: 250–350 ng/mL for men 30–45, 200–300 ng/mL for men 45+. Above 350 ng/mL chronically correlates with increased mitogenic signaling — don’t push higher just because you can.

Cycle support: CJC-1295 doesn’t suppress your HPG axis the way androgens do, so no PCT required. Fasting glucose and HbA1c should be checked — GH is mildly diabetogenic, and pushing IGF-1 high while eating dirty creates insulin resistance.

Stacking Recommendations

Target Audience

CJC-1295 is for the Enhanced Man over 30 whose GH output has dropped 14% per decade since age 21 and who wants the recovery, sleep depth, and body composition benefits of restored GH signaling — without the cost, water retention, and aromatase amplification of injectable HGH. It’s particularly appropriate for athletes with chronic soft-tissue injuries, men on TRT plateauing in body composition, and longevity-minded biohackers who want IGF-1 in the upper-normal range rather than blasted into mitogenic territory.

It is not for men under 25 (your natural GH is fine — fix sleep and training first), for anyone with active or recently treated cancer (IGF-1 promotes mitosis), or for people unwilling to commit to subcutaneous injections 1–3 times daily.

Timeline: What to Expect

Interesting Perspectives

The DAC scam most clinics run: Many telehealth peptide clinics push CJC-1295 with DAC because once-weekly dosing is easier to sell. The problem is that flattening GH into a continuous bleed contradicts the entire reason endogenous GH evolved as a pulse. Pulsatile signaling is what drives downstream IGF-1 sensitivity. A flat GH curve causes IGF-1 receptor downregulation over time — explaining why so many DAC users report diminishing returns at month three.

The gut connection nobody discusses: CJC-1295 + ipamorelin’s effect on gut motility and visceral fat is partially mediated through the vagus nerve and the GH–gut axis. Patients report improved digestion and reduced bloating within weeks — an unintentional but consistent off-target benefit.

Cross-domain insight from longevity research: Long-lived populations (Laron syndrome dwarfs, IGF-1-null mice) have low IGF-1. This is the central tension in GH therapy — short-term recomposition and recovery come at the potential cost of long-term mortality risk if pushed chronically. Tony’s framework: pulse it for body composition windows, return to baseline for longevity windows. Don’t run GH-pathway compounds 365 days a year.

Contrarian take: Most “low GH” diagnoses in middle-aged men are actually a downstream sleep problem. Fix sleep depth (cold room, no blue light past 8 PM, melatonin titration, magnesium glycinate) and 60% of the deficit clears without any peptide. CJC-1295 amplifies an already-healthy system — it doesn’t rescue a broken one.

FAQ

What is CJC-1295? CJC-1295 is a synthetic analog of GHRH (1-29) modified to resist DPP-IV degradation. It triggers endogenous growth hormone release from the pituitary by activating GHRH receptors.

How much CJC-1295 should I take? The standard protocol is 100 mcg of Modified GRF 1-29 (no DAC) subcutaneously, 1–3 times daily, typically stacked with 100 mcg ipamorelin per injection. Inject in a fasted state and wait 20–30 minutes before eating.

What are the side effects of CJC-1295? Common effects include injection-site flushing, mild fluid retention in the first two weeks, vivid dreams, increased hunger (from the ipamorelin component), and tingling in extremities. Long-term, elevated IGF-1 can mildly raise fasting glucose — monitor HbA1c.

Can I stack CJC-1295 with testosterone? Yes. GH and androgens act on independent receptor systems — they synergize without competition. This is the foundation of most Enhanced Athlete recomposition protocols.

Who should use CJC-1295? Enhanced Men over 30 wanting GH-axis amplification for recovery, sleep, and body composition — without the cost, water retention, and exogenous shutdown of injectable HGH. Avoid if under 25, with active cancer history, or unwilling to commit to daily injections.

Related Reading on tonyhuge.is

For the full overview of how GH-axis peptides fit Tony’s framework, start with the Enhanced Athlete Protocol — Peptides hub. Pair this article with the ultimate peptide stack guide and the CJC-1295 vs ipamorelin comparison piece for direct stacking logic. For the foundational framework, read Tony Huge Law 1 — Governors vs Accelerators. And for bloodwork standards, see the Enhanced Athlete Protocol — Bloodwork hub.